The Diabetes treatment devices market includes a wide range of medical devices used to manage and monitor diabetes, such as insulin pumps, continuous glucose monitors (CGMs), pens, injection devices, and smart glucose meters. Growth is driven by the rising prevalence of diabetes worldwide, increasing focus on patient self-management, and technological innovations like digital connectivity, smartphone integration, and AI-powered analytics. These devices enable better glycemic control, improved adherence, and enhanced quality of life for patients. As healthcare systems embrace remote monitoring and telehealth, diabetes treatment devices are becoming more accessible and effective in managing chronic metabolic disease across regions.
According to Fortune Business Insights, the global diabetes treatment devices market was valued at USD 10.83 billion in 2018 and is projected to reach USD 22.83 billion by 2032, exhibiting a CAGR of 5.5% during the forecast period. In 2018, North America dominated the diabetes treatment devices market with a market share of 40.44%.
Top Companies in the Market
- F. Hoffmann‑La Roche Ltd
- Tandem Diabetes Care, Inc.
- B. Braun Melsungen AG
- Medtronic
- BD
- Novo Nordisk A/S
- Abbott
- Sanofi
- Other players
Key Industry Development
In March 2021, F. Hoffmann‑La Roche Ltd introduced the Accu‑Check Instant system—an advanced blood glucose monitoring platform designed to support their integrated, personalized diabetes management strategy. The launch signifies a commitment to empowering patients with real-time data and seamless integration into digital care pathways .
Market Drivers & Restraints
1. Rising Prevalence of Diabetes
Diabetes continues to surge worldwide, fueled by urban lifestyles, sedentary behavior, and rising obesity rates. Organizations like the International Diabetes Federation have reported over 425 million affected individuals in 2017, with projections reaching 629 million by 2045 . This expanding patient base is a critical growth driver.
2. Technological Advancements & R&D
Healthcare technology innovations—such as minimally invasive infusion systems, digital integration, and smart insulin pens—are transforming diabetes care. For example, in February 2019, Tandem received FDA approval for the t:slim X2, the first interoperable insulin pump . Meanwhile, partnerships like Abbott and Tandem's agreement highlight trend toward integrated device ecosystems .
3. Growing Investment & Collaboration
Leading players are accelerating R&D through strategic collaborations. The FDA approvals and smart-device integrations—such as Roche and Biocorp’s smart insulin pen partnership—are driving market innovation .
4. Rising Healthcare Awareness & Insulin Dependency
The growing campaign for diabetes awareness and the increasing number of insulin-dependent (type 1) patients have created demand for user-friendly, home-use devices .
Restraints
- High cost of device innovation and approval can create entry barriers for emerging players.
- Complexity surrounding device approvals and reimbursement further restricts market expansion.
Market Report Coverage
The diabetes treatment devices market report provides a comprehensive analysis of:
- Market size and projections (2019–2032)
- Segmentation by product and distribution channel
- Competitive landscape with key player strategies and profiles
- Technological advancements, R&D trends, and regulatory snapshots
Market Competitive Landscape
Major firms like Roche, Medtronic, Tandem, Novo Nordisk, and Abbott dominate through continuous product development and global distribution networks. Roche’s Accu‑Check Instant system and Tandem's t:slim X2 epitomize the shift toward smarter, integrated diabetes management tools .
Market Segments
By Product
The product mix includes insulin pens, pumps, jet injectors, syringes, and others. The insulin pens segment is witnessing robust growth, driven by preference for minimally invasive, reusable, and prefilled devices. The insulin pumps segment is also expanding significantly due to the increasing prevalence of type 1 diabetes .
By Distribution Channel
Two primary channels are institutional and retail sales. The retail sales segment leads the market, propelled by increased access to private-label brands in pharmacies, and partnerships like AgaMatrix and Perrigo that have enhanced point-of-care device availability .
Regional Insights
North America
Dominating with a 40.44% market share in 2018, North America led with USD 4.38 billion in revenue . Strong healthcare infrastructure, high insurance penetration, and leading R&D investments drive growth across the U.S. and Canada.
Asia-Pacific
Projected to register the highest growth rate, fuelled by increasing diabetes incidence and demand for advanced infusion systems in populous countries such as China and India .
Europe
Europe is poised for substantial gains, underpinned by rising diabetes awareness, national healthcare initiatives, and early adoption of withdrawal devices .
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/diabetes-treatment-devices-market-100777
Future Market Scope
The market’s future trajectory is driven by:
- 📱 Personalized AI-driven insulin dosing and predictive analytics
- 🔋 Non-invasive continuous glucose monitoring and patch-based insulin delivery
- 🤝 Further consolidation via acquisitions and tech partnerships for integrated ecosystems
As digital health evolves, devices enabling closed-loop systems—known as artificial pancreas—hold promise for revolutionizing diabetes care .
Conclusion
In summary, the diabetes treatment devices market is on a robust growth path. Valued at USD 10.83 billion in 2018 and on track to reach USD 22.83 billion by 2032, the sector is thriving on innovation, rising disease burden, and growing patient empowerment. Future gains depend on overcoming cost barriers, regulatory complexity, and building accessible, patient-centric solutions. Major players who can combine cutting-edge technology with affordability and ease of use will lead the charge in transforming diabetes care worldwide.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
0 comment